Hostname: page-component-55f67697df-q9hcs Total loading time: 0 Render date: 2025-05-11T15:03:45.110Z Has data issue: false hasContentIssue false
  • English
  • Français

Botulism: Cause, Effects, Diagnosis, Clinical and Laboratory Identification, and Treatment Modalities

Published online by Cambridge University Press:  08 April 2013

Zygmunt F. Dembek ,
Leonard A. Smith  and
Janice M. Rusnak
Get access Rights & Permissions [Opens in a new window]

Abstract

Botulism is a neuroparalytic disease caused by neurotoxins produced by the bacteria Clostridium botulinum. Botulinum neurotoxins (BoNTs) are among the most potent naturally occurring toxins and are a category A biological threat agent. The 7 toxin serotypes of BoNTs (serotypes A–G) have different toxicities, act through 3 different intracellular protein targets, and exhibit different durations of effect. Botulism may follow ingestion of food contaminated with BoNT, from toxin production of C botulinum present in the intestine or wounds, or from inhalation of aerosolized toxin. Intoxication classically presents as an acute, symmetrical, descending flaccid paralysis. Early diagnosis is important because antitoxin therapy is most effective when administered early. Confirmatory testing of botulism with BoNT assays or C botulinum cultures is time-consuming, and may be insensitive in the diagnosis of inhalational botulism and in as many as 32% of food-borne botulism cases. Therefore, the decision to initiate botulinum antitoxin therapy is primarily based on symptoms and physical examination findings that are consistent with botulism, with support of epidemiological history and electrophysiological testing. Modern clinical practice and antitoxin treatment has reduced botulism mortality rates from ∼60% to ≤10%. The pentavalent botulinum toxoid is an investigational product and has been used for more than 45 years in at-risk laboratory workers to protect against toxin serotypes A to E. Due to declining immunogenicity and potency of the pentavalent botulinum toxoid, novel vaccine candidates are being developed. (Disaster Med Public Health Preparedness. 2007;1:122–134)

Keywords

botulismbiological weaponbioterrorism
Type
Invited Review
Information
Disaster Medicine and Public Health Preparedness , Volume 1 , Issue 2 , November 2007 , pp. 122 - 134
Copyright
Copyright © Society for Disaster Medicine and Public Health, Inc. 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Nishiura, H.Incubation period as a clinical predictor of botulism: analysis of previous izushi-borne outbreaks in Hokkaido, Japan, from 1951 to 1965. Epidemiol Infect. 2007;135:126–130.Google Scholar
2.Shapiro, RL, Hatheway, C, Swerdlow, DL.Botulism in the United States: a clinical and epidemiological review. Ann Intern Med. 1998;129:221–228.Google Scholar
3.White, SM.Chemical and biological weapons. Implications for anaesthesia and intensive care. Br J Anaesth. 2002;89:306–324.Google Scholar
4.Hill, EV Botulism. Summary Report on B.W. Investigations. Memorandum to Alden C. Waitt, Chief Chemical Corps, United States Army, December 12, 1947; tab D. Archived at the US Library of Congress. Washington, DC: 1947.Google Scholar
5. Cochrane RC. Biological Warfare Research in the United States. In: History of the Chemical Warfare Service in World War II (01 July 1940–15 August 1945), Vol 2. Historical Section, Plans, Training and Intelligence Division, Office of Chief, Chemical Corps, US Department of the Army. Unclassified. Archived at the US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD; 1947.Google Scholar
6.Bernstein, BJ.The birth of the US biological-warfare program. Sci Am. 1987;256:116–121.Google Scholar
7.Bernstein, BJOrigins of the U.S. biological warfare program. Wright S. Preventing a Biological Arms Race. Cambridge, MA: MIT Press; 1990: 9–25.Google Scholar
8.Franz, DR, Parrott, CD, Takafuji, ET. The U.S. biological warfare and biological defense programs. Slidell FR, Takafuji ET, Franz DR. Textbook of Military Medicine, Part I: Warfare, Weaponry, and Then Casualty: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Borden Institute, Walter Reed Army Medical Center; 1997: 425–436.Google Scholar
9. Biological and Toxin Weapons Convention Web site. http://www.opbw.org. Accessed June 14, 2006.Google Scholar
10.Tenth Report of the Executive Chairman of the Special Commission Established by the Secretary-General Pursuant to Paragraph 9. 10(b) (I) of Security Council Resolution 687 (1991), and Paragraph 3 of Resolution 699 (1991) on the Activities of the Special Commission. S/1995/1038. New York: United Nations Security Council; 1995.Google Scholar
11.Bozheyeva, G, Kunakbayev, Y, Yeleukenov, D.Former Soviet Biological Weapons Facilities in Kazakhstan: Past, Present and Future. Occasional paper No. 1. Monterey, CA: Center for Nonproliferation Studies, Monterey Institute of International Studies; 1999: 1–20.Google Scholar
12. Miller J. At bleak Asian site, killer germs survive. New York Times. June 2, 1999: A1, A10.Google Scholar
13.Alibek, K, Handleman, S.Biohazard. New York: Random House; 1999.Google Scholar
14. 1998 Congressional Hearings. Statement by Dr Kenneth Alibek before the Joint Economic Committee, US Congress, Wednesday, May 20, 1998. Terrorist and Intelligence Operations: Potential Impact on the US Economy. GlobalSecurity.org Web site. http://www.globalsecurity.org/intell/library/congress/1998_hr/alibek.htm. Accessed October 10, 2007.Google Scholar
15. Zilinskas RA. Iraq’s biological weapons: the past and future? JAMA. 1997;278:418–424.CrossRefGoogle Scholar
16.Blix, H.Disarming Iraq. New York: Pantheon Books; 2004.Google Scholar
17.Van Ermengen, E.Ueber einen neuren anaeroben Bacillus und seine beziehungen zum botilismus. Z Hyg Infektionskrankh. 1897;26:1–56.Google Scholar
18.Sobel, J, Tucker, N, Sulka, A, McLaughlin, J, Maslanka, S.Foodborne botulism in the United States, 1900-2000. Emerg Infect Dis. 2004;10:1606–1611.Google Scholar
19.Smart, JL, Jones, TO, Clegg, FG, McMurray, MJ.Poultry waste associated type C botulism in cattle. Epidemiol Infect. 1987;98:73–79.Google Scholar
20.Whitlock, RH, Buckley, C.Botulism. Vet Clin N Am Eq Proc. 1997;13:107–128.Google Scholar
21.McLaughlin, JB, Sobel, J, Lynn, T, Funk, E, Middaugh, JP.Botulism type E outbreak associated with eating a beached whale, Alaska. Emerg Infect Dis. 2004;10:1685–1687.Google Scholar
22.Sugishima, M.Aum Shinrikyo and the Japanese law on bioterrorism. Prehosp Disaster Med. 2003;18:179–183.Google Scholar
23.Leitenberg, M.Aum Shinrikyo’s efforts to produce biological weapons: a case study in the serial propagation of misinformation. Terrorism Political Violence. 1999;11:149–158.Google Scholar
24. Revkin AC. Arrests reveal threat of biological weapons. Published February 21, 1998. New York Times. http://query.nytimes.com/gst/fullpage.html?res=9E0DE5D71E3FF932A15751C0A96E958260. Accessed October 11, 2007.Google Scholar
25.Torok, TJ, Tauxe, RV, Wise, RP, et alA large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA. 1997;278:389–395.Google Scholar
26.Carus, WS. The Rajneeshees (1984). Tucker JB. Toxic Terror: Assessing Terrorist Use of Chemical and Biological Weapons. Cambridge, MA: MIT Press; 2000: 115–137.Google Scholar
27.Miller, J, Engelberg, S, Broad, W.Germs: Biological Weapons and America’s Secret War. New York: Simon & Schuster; 2001: 15–33.Google Scholar
28.Smith, LABacterial protein toxins as biological weapons.Alouf JE, Popoff MR. The Comprehensive Sourcebook of Bacterial Protein Toxins. London: Academic Press; 2006: 1019–1030.Google Scholar
29.Hennessy, TW, Hedberg, CW, Slutsker, L, et alA national outbreak of Salmonella enteritidis from ice cream. N Engl J Med. 1996;334:1281–1296.Google Scholar
30.Ryan, CA, Nickels, MK, Hargrett-Bean, NT, et alMassive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. JAMA. 1987;258:3269–3274.Google Scholar
31.Wein, LM, Liu, Y.Analyzing a bioterrorist attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A. 2005;102:9984–9989.Google Scholar
32.Alberts, B.Modeling attacks on the food supply. Proc Natl Acad Sci U S A. 2005;102:9737–9738.Google Scholar
33.Dembek, ZFModeling for bioterrorism incidents.Lindler LE, Lebeda FJ, Korch, GW. Biological Weapons Defense: Infectious Disease and Counterbioterrorism. Totowa, NJ: Humana Press; 2005: 23–40.Google Scholar
34.Centers for Disease Control and Prevention Outbreak of gastroenteritis associated with an interactive water fountain at a beachside park–Florida, 1999. MMWR. 2000;49:565–568.Google Scholar
35.Ward, BQ, Carroll, BJ, Garrett, ES, Reese, GB.Survey of the U.S. Gulf Coast for the presence of Clostridium botulinum. Appl Microbiol. 1967;15:629–36.Google Scholar
36.Smith, LDS.The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States. Health Lab Sci. 1978;15:74–80.Google Scholar
37.Shone, CC, Tranter, HS. Growth of Clostridia and preparation of their neurotoxins. Montecucco C. Current Topics in Microbiology: Clostridial Neurotoxins: The Molecular Pathogenesis of Tetanus and Botulism. 195 Berlin: Springer-Verlag; 1995: 143–160.Google Scholar
38.Arnon, SS, Schechter, R, Inglesby, TV, et alBotulinum toxin as a biological weapon. Medical and public health management. JAMA. 2001;285:1059–1070.Google Scholar
39.Hatheway, CLClostridium botulinum and other clostridia that produce botulinum neurotoxins. Hauschild AHW, Dodds KL. Clostridium botulinum: Ecology and Control in Foods. New York: Marcel Dekker; 1992: 3–10.Google Scholar
40.Halpern, JL, Smith, LA, Seamon, KB, Groover, KA, Habig, WH.Sequence homology between tetanus and botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1989;40:1213–1218.Google Scholar
41.Hall, JD, McCroskey, LM, Pincomb, BJ, Hatheway, CL.Isolation of an organism resembling Clostridium baratii which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985;21:654–655.Google Scholar
42.Aureli, P, Fenicia, L, Pasolini, B, Gianfranceschi, M, McCroskey, LM, Hatheway, CL.Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis. 1986;154:207–211.CrossRefGoogle ScholarPubMed
43.Barash, JR, Tang, TWH, Arnon, SS.First case of infant botulism caused by Clostridium baratii type F in California. J Clin Microbiol. 2005;43:4280–4282.Google Scholar
44.Sonnabend, O, Sonnabend, O, Heinzle, R, Sigrist, T, Dirnhofer, R, Krech, U.Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths. J Infect Dis. 1981;143:22–27.Google Scholar
45.Middlebrook, JL, Franz, DR. Botulinum toxins.Slidell FR, Takafuji ET, Franz DR. Textbook of Military Medicine, Part I: Warfare, Weaponry, and Then Casualty: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Borden Institute, Walter Reed Army Medical Center; 1997: 643–654.Google Scholar
46.Aktories, K, Barth, H.Clostridium botulinum C2 toxin—new insights into the cellular up-take of the actin-ADP-ribosylating toxin. Int J Med Microbiol. 2004;293:557–64.Google Scholar
47.Barth, H, Aktories, K, Popoff, MR, Stiles, BG.Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev. 2004;68:373–402.Google Scholar
48.Ohishi, I.Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect Immun. 1984;43:487–490.Google Scholar
49.Scott, AB, Suzuki, D.Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3:333–335.Google Scholar
50.Franz, DR, Pitt, LM, Clayton, MA, Hanes, MA, Rose, KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism.DasGupta BR. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York: Plenum Press; 1993: 473–476.Google Scholar
51.Woodruff, BA, Griffin, AM, McCroskey, LM, et alClinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis. 1992;166:1281–1286.Google Scholar
52.Swaminathan, S, Eswaramoorthy, S.Structural analysis of the catalytic and biding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 2000;7:696–699.Google Scholar
53.Lamanna, C.The most poisonous poison. Science. 1959;130:763–772.Google Scholar
54.Fu, FN, Lomneth, RB, Cai, SS, et alRole of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry. 1998;37:5267–5278.Google Scholar
55.Gill, DM.Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:86–94.Google Scholar
56.De Paiva, A, Meunier, FA, Molgo, J, Aoki, KR, Dolly, JO.Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–3205.Google Scholar
57.Foran, P, Mohammed, N, Lisk, G, et alEvaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared to the long-lasting type A: basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278:1363–1371.Google Scholar
58.Aoki, KR, Guyer, B.Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8 (Suppl 5):21–29.Google Scholar
59.Simpson, LL.Identification of the major steps in botulinum toxin action. Ann Rev Pharmacol Toxicol. 2004;44:167–193.Google Scholar
60. Pellizzari R, Rossetto O, Washbourne P, Tonello F, Nocotera PL, Monteccuco C. In vitro biological activity and toxicity of tetanus and botulinum neurotoxins. Toxicol Lett. 1998;102–103:191–197.Google Scholar
61.Habermann, E. Clostridial neurotoxins and the central nervous system: functional studies on isolated preparations.Simpson LL. Botulinum Neurotoxin and Tetanus Toxin. New York: Academic Press; 1989: 53–67.CrossRefGoogle Scholar
62.Rossetto, O, deBernard, M, Pellizzari, R, et alBacterial toxins with intracellular protease activity. Clin Chim Acta. 2000;291:189–199.Google Scholar
63.Tacket, CO, Shandera, WX, Mann, JM, et alEquine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984;76:794–798.Google Scholar
64.Hughes, JM, Blumenthal, JR, Merson, MH, Lombard, GL, JrDowell, VR, Gangarosa, EJ.Clinical features of types A and B food-borne botulism. Ann Intern Med. 1981;95:442–445.Google Scholar
65.Maroon, JC.Late effects of botulinum intoxication. JAMA. 1977;238:129.Google Scholar
66.Mann, JM, Martin, S, Hoffman, R, Marrazzo, S.Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health. 1981;71:266–269.Google Scholar
67.Varma, JK, Katstadze, G, Moiscrafishvili, M, et alSigns and symptoms predictive of death in patients with foodborne botulism–Republic of Georgia, 1989–2002. Clin Infect Dis. 2004;39:357–62.Google Scholar
68.Holzer, E.Botulism caused by inhalation. Med Klin. 1962;41:1735–1740.Google Scholar
69.Werner, SB, Passaro, D, McGee, J, Schechter, R, Vugia, DJ.Wound botulism in California, 1951–1998: recent epidemic in heroin injectors. Clin Infect Dis. 2000;31:1018–1024.Google Scholar
70.Maselli, RA, Bakshi, N.American Association of Electrodiagnostic Medicine case report 16: botulism. Muscle Nerve. 2000;23:1137–1144.Google Scholar
71.Cherington, M.Clinical spectrum of botulism. Muscle Nerve. 1998;21:701–710.Google Scholar
72.Padua, L, Aprile, I, Monaco, ML, et alNeurophysiological assessment in the diagnosis of botulism: usefulness of single-fiber EMG. Muscle Nerve. 1999;22:1388–1392.Google Scholar
73.Franz, DR, Jahrling, PB, Friedlander, AM, et alClinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399–411.CrossRefGoogle ScholarPubMed
74.Heymann, DL.Control of Communicable Diseases in Man. 18th ed. Washington, DC: American Public Health Association; 2004: 69–75.Google Scholar
75.Chao, HY, Wang, YC, Tang, SS, Liu, HW.A highly sensitive immuno-polymerase chain reaction assay for Clostridium botulinum neurotoxin type A. Toxicon. 2004;43:27–34.Google Scholar
76.Akbulut, D, Grant, KA, McLauchlin, J.Improvement in laboratory diagnosis of wound botulism and tetanus among injecting illicit-drug users by use of real-time PCR assays for neurotoxin gene fragments. J Clin Microbiol. 2005;43:4342–4348.Google Scholar
77.Kongsaengdao, S, Samintarapanya, K, Rusmeechan, S, et alAn outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis. 2006;43:1247–1256.Google Scholar
78.Marks, JD.Medical aspects of biologic toxins. Anesthesiol Clin N Am. 2004;22:509–532.Google Scholar
79.Black, TS. Clostridium botulinum (botulism).Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingston; 2000: 2543–2548.Google Scholar
80.Gottlieb, SL, Kretsinger, K, Tarkhashvili, N, et alLong-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis. 2007;45:174–180.Google Scholar
81.Iida, H.Specific antitoxin therapy in type E botulism. Jpn J Med Sci Biol. 1963;16:311–313.Google Scholar
82.Infant botulism–New York City, 2001–2002. MMWR. 2003;52:21–24.Google Scholar
83.Fox, CK, Keet, CA, Strober, JB.Recent advances in infant botulism. Pediatr Neurol. 2005;32:149–154.Google Scholar
84.Arnon, SS. Infant botulism.Feigin RD, Cheny JD. Textbook of Pediatric Infectious Disease, 4th ed. Philadelphia: WB Saunders; 1998: 1758–1766.Google Scholar
85. Advanced topics on medical defense against biological agents: botulinum toxin. Christian E. Sandrock interview. Satellite telecast September 20, 2006. Course #21106 archived on http://www.swankhealth.com. Accessed June 29, 2007.Google Scholar
86. Advanced topics on medical defense against biological agents: botulinum toxin, Steven M. Marcus interview. Satellite telecast September 20, 2006. http://www.swankhealth.com/botox. Accessed June 29, 2007.Google Scholar
87. Allergan’s BOTOX not cause of botulism in Florida patients. Medical News Today. Published December 13, 2004. http://www.medicalnewstoday.com/medicalnews.php?newsid=17720. Accessed June 29, 2007.Google Scholar
88. Reports blame Florida botulism cases on misused toxin. Center for Infectious Disease Research and Policy, University of Minnesota. Published December 15, 2004. http://www.cidrap.umn.edu/cidrap/content/bt/botulism/news/dec1504botulism.html. Accessed June 29, 2007.Google Scholar
89.Chertow, DS, Tan, ET, Maslanka, SE, et alBotulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296:2476–2479.Google Scholar
90.Souyah, N, Karim, H, Kamin, SS, McArdle, J, Marcus, S.Severe botulism after focal injection of botulinum toxin. Neurology. 2006;67:1855–1856.Google Scholar
91.Botulism from home-canned bamboo shoots–Nan province, Thailand, March 2006. MMWR. 2006;55:389–392.Google Scholar
92.Wongtanate, M, Sucharitchan, N, Tantisiriwit, K, et alSigns and symptoms predictive of respiratory failure in patients with foodborne botulism in Thailand. Am J Trop Med Hyg. 2007;77:386–389.Google Scholar
93.Ungchusak, K, Chunsuttiwat, S, Braden, CR, et alThe need for global planned mobilization of essential medicine: lessons from a massive Thai botulism outbreak. Bull WHO. 2007;85:238–240.Google Scholar
94. Evaluation of Safety and Immunogenicity of Pentavalent Botulinum Toxoid (A–E) Administered to Healthy Volunteers, Log A-9241, US Army, Office of the Surgeon General, February 2001.Google Scholar
95.Cardella, MA, Wright, GG.Specifications for Manufacture of Botulism Toxoids, Adsorbed, Pentavalent, Types ABCDE (Technical Study 46). Ft Detrick, MD: Medical Investigation Division, US Army Biological Laboratories; 1964.Google Scholar
96.Rusnak, JM, Kortepeter, MG, Hawley, RJ, Anderson, AO, Boudreau, E, Eitzen, E.Risk of occupationally-acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecurity Bioterrorism. 2004;2:281–293.Google Scholar
97.Siegel, LS.Human Immune Response to Botulinum Pentavalent (ABCDE) Toxoid Determined by a Neutralization Test and by an Enzyme-Linked Immunosorbent Assay. J Clin Microbiol. 1988;26:2351–2356.CrossRefGoogle ScholarPubMed
98. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol. In press.Google Scholar
99. Brown JE, Parker GW, Pitt LM, et al. Protective efficacy of monkey pentavalent botulinum toxoid vaccine on an abbreviated immunization schedule [abstract]. ASM Int Conf Molec Genet Pathogen Clostridia. Rio Rico, AZ, January 11–14, 1995.Google Scholar
100.Fiock, MA, Cardella, MA, Gearinger, NF.Studies on immunity to toxins of Clostridium botulinum. IX. Immunologic response of man to purified A,B,C,D, and E botulinum toxoid. J Immunol. 1963;90:967–702.Google Scholar
101. Rusnak JM, Smith L, Boudreau E, et al. Decreased immunogenicity of botulinum Pentavalent Toxoid to Toxins B and E [abstract S10]. 6th Annual Conference on Vaccine Research. May 5–7, 2003, Arlington, VA.Google Scholar
102. Battelle Memorial Institute, Chemical Warfare/Chemical and Biological Defense Information Analysis Center. Evaluation of Safety and Immunogenicity of Pentavalent Botulinum Development of Safe and Effective Products to Exposure to Biological Chemical Warfare Agents; 2001.Google Scholar
103. Battelle Memorial Institute, Chemical Warfare/Chemical and Biological Defense Information Analysis Center. Evaluation of Safety and Immunogenicity of Pentavalent Botulinum Toxoid (A–E) Administered to Healthy Volunteers–Continuation of Study for Determination of Booster Vaccination Interval; 2002.Google Scholar
104. Evaluation of Safety and Immunogenicity of Pentavalent Botulinum Toxoid (A–E) Administered to Healthy Volunteers, Log A-9241, US Army, Office of the Surgeon General; 2001.Google Scholar
105.Serologic Response to Anthrax and Botulinum Vaccines. Final Study Report, Protocol FY 92-5, M 109, Log A-5747. US Army, Office of the Surgeon General; 1997.Google Scholar
106.Gelzleichter, TR, Myers, MA, Menton, RG, Niemuth, NA, Matthews, MC, Langford, MJ.Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol. 1999;19:S35–S38.Google Scholar
107.Edelman, R, Wasserman, SS, Bodison, SA, Perry, JG, O’Donnoghue, M, DeTolla, LJ.Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers. Vaccine. 2003;21:4335–47.Google Scholar
108.Torii, Y, Tokumaru, Y, Kawaguchi, S, et alProduction and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine. 2002;20:2556–2561.Google Scholar
109.Holley, JL, Elmore, M, Mauchline, M, Minton, N, Titball, RW.Cloning expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine. 2000;19:288–292.Google Scholar
110.Byrne, MP, Smith, TJ, Montgomery, VA, Smith, LA.Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun. 1998;66:4817–4822.Google Scholar
111.Clayton, J, Middlebrook, FL.Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine. 2000;18:1855–1862.Google Scholar
112.Shyu, RH, Shaio, MF, Tang, SS, et alDNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci. 2000;7:51–57.Google Scholar
113.Potter, KJ, Bevins, MA, Vassilieva, EV, et alProduction and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast, Picia pastoris. Protein Exp Purif. 1998;13:357–365.Google Scholar
114.Kyatkin, N, Maksymowych, AB, Simpson, LL.Induction of an immune response by oral administration of recombinant botulinum toxin. Infect Immun. 1997;65:4586–4591.Google Scholar
115.Foynes, S, Holley, JL, Garmory, HS, Titball, RW, Fairweather, NF.Vaccination against type F botulinum toxin using attenuated Salmonella enterica var typhimurium strains expressing the BoNT/F hc fragment. Vaccine. 2003;21:1052–1059.Google Scholar
116.Smith, LA, Jensen, JM, Montgomery, VA, Brown, DR, Ahmed, SA, Smith, TJ.Roads from vaccines to therapies. Mov Disord. 2004;19:S48–S52.Google Scholar
117.Middlebrook, JL.Protection strategies against botulinum toxin. Adv Exp Med Biol. 1995;383:93–98.Google Scholar
118.Park, JB, Simpson, LL.Progress toward development of an inhalation vaccine against botulinum toxin. Expert Rev Vaccines. 2004;3:477–487.CrossRefGoogle ScholarPubMed
119.Park, JB, Simpson, LL.Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun. 2003;71:1147–1154.Google Scholar
120.Byrne, MP, Smith, LA.Development of vaccines for prevention of botulism. Biochimie. 2000;82:955–66.Google Scholar